DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time

We report on the immunogenicity and clinical effects in a phase I/II dose escalation trial of a DNA fusion vaccine in patients with prostate cancer. The vaccine encodes a domain (DOM) from fragment C of tetanus toxin linked to an HLA-A2-binding epitope from prostate-specific membrane antigen (PSMA),...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Chudley, Lindsey, McCann, Katy, Mander, Ann, Tjelle, Torunn, Campos-Perez, Juan, Godeseth, Rosemary, Creak, Antonia, Dobbyn, James, Johnson, Bernadette, Bass, Paul, Heath, Catherine, Kerr, Paul, Mathiesen, Iacob, Dearnaley, David, Stevenson, Freda, Ottensmeier, Christian
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer-Verlag 2012
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3493666/
https://ncbi.nlm.nih.gov/pubmed/22729556
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-012-1270-0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares